bullish
Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October
339 Views28 Sep 2020 04:21
CureVac shares have been under selling pressure and fell ~20% in September. For the same period shares of key rivals Moderna and BioNTech rose 7%...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Rising
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Price Chart(Sign Up to Access)
- CureVac Stock May Surge Another 20-30% Under New Bull-Case Scenario23 Nov 2020
- Success of Moderna’s COVID-19 Vaccine May Give a Boost to Stocks of Messenger RNA Companies13 Nov 2020
- CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech21 Aug 2020
- How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share17 Aug 2020
x